<DOC>
	<DOCNO>NCT02813369</DOCNO>
	<brief_summary>This post-authorization observational safety study ( PASS ) monitor clinically important identify potential risk within cohort patient treat naloxegol , include occurrence bowel perforation , acute myocardial infarction ( MI ) , stroke , cardiovascular ( CV ) -specific mortality , all-cause mortality , hypertension , opioid withdrawal , abdominal pain , diarrhea , syncope , change pain severity . This study part broad post-marketing commitment augment routine evaluation safety profile naloxegol clinical practice .</brief_summary>
	<brief_title>Naloxegol Health Outcomes PASS</brief_title>
	<detailed_description>The overall research goal study provide additional data characterize safety naloxegol indicated population within at-risk vulnerable population identify naloxegol risk management plan ( RMP ) describe type frequency identify potential risk ( include bowel perforation , acute MI , stroke , CV-specific mortality , all-cause mortality , hypertension , opioid withdrawal , abdominal pain , diarrhea , syncope , change pain severity ) patient ≥18 year age diagnose non-cancer pain treat opioids chronically subsequently treat naloxegol routine post-authorization use . The primary objective study assess incidence risk bowel perforation , acute MI , stroke , all-cause mortality , hypertension patient treat naloxegol ( Naloxegol Inception Cohort , ( NIC ) ) , Concurrent Reference Cohort ( CRC ) , pre-specified sub-populations include patient age ≥65 year , pregnant patient , patient prior cardiovascular risk , patient prior renal hepatic impairment , patient concurrent methadone use , patient concurrent use cytochrome P450 ( CYP ) 3A inhibitors/inducer P-glycoprotein ( Pgp ) modulators . An exploratory objective study assess incidence risk CV-specific mortality , opioid withdrawal , abdominal pain , diarrhea , syncope , change pain severity patient treat naloxegol ( NIC ) , CRC , pre-specified sub-populations include patient age ≥65 year , pregnant patient , patient prior cardiovascular risk , patient prior renal hepatic impairment , patient concurrent methadone use , patient concurrent use CYP3A inhibitors/inducer Pgp modulators .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Laxatives</mesh_term>
	<mesh_term>Cathartics</mesh_term>
	<mesh_term>Naloxegol</mesh_term>
	<mesh_term>Narcotic Antagonists</mesh_term>
	<criteria>1 . Patient receive new prescription naloxegol nonPAMORA laxative . ( Note : Only nonPAMORA laxative approved/marketed European Union time naloxegol authorize permit . ) 1 . Patients &lt; 18 year age cohort entry date 2 . Patients &lt; 1 year continuous data available prior cohort entry date 3 . Patients without exposure current regular opioid use define &gt; 30 day opioid exposure within 180 day prior inclusive cohort entry date 4 . Patients evidence cancer indicator ( diagnosis treatment ) prior cohort entry date 5 . Exposure PAMORA laxatives , alvimopan , methylnaltrexone , naloxone + opioid combination ( include fixeddose combination ) prior cohort entry date</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>